Obio Technology (Shanghai) Valuation
Is 688238 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688238 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 688238 (CN¥5.6) is trading below our estimate of fair value (CN¥16.29)
Significantly Below Fair Value: 688238 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688238?
Other financial metrics that can be useful for relative valuation.
What is 688238's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥3.63b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.6x |
Enterprise Value/EBITDA | -16.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 688238's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.5x | ||
688202 Shanghai Medicilon | 4.8x | 51.6% | CN¥4.7b |
301230 PharmaResources (Shanghai) | 6.5x | 20.9% | CN¥3.4b |
300813 Zhejiang Tailin BioEngineeringLtd | 8.3x | n/a | CN¥2.6b |
688315 Novogene | 2.5x | 17.5% | CN¥5.3b |
688238 Obio Technology (Shanghai) | 14.4x | 22.8% | CN¥3.6b |
Price-To-Sales vs Peers: 688238 is expensive based on its Price-To-Sales Ratio (14.4x) compared to the peer average (5.5x).
Price to Earnings Ratio vs Industry
How does 688238's PE Ratio compare vs other companies in the CN Life Sciences Industry?
Price-To-Sales vs Industry: 688238 is expensive based on its Price-To-Sales Ratio (14.4x) compared to the CN Life Sciences industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is 688238's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 14.4x |
Fair PS Ratio | 2.8x |
Price-To-Sales vs Fair Ratio: 688238 is expensive based on its Price-To-Sales Ratio (14.4x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.